[
    [
        {
            "time": "",
            "orginal_text": "药明康德（603259.SH）：认缴120Capital的1588.0899万美元份额",
            "features": {
                "keywords": [
                    "药明康德",
                    "认缴",
                    "120Capital",
                    "医疗健康",
                    "私募基金"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德（603259.SH）：认缴120Capital的1588.0899万美元份额",
            "scores": {
                "News_content": "药明康德（603259.SH）：认缴120Capital的1588.0899万美元份额",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "四大CXO企业2020年成绩单大比拼：药明康德营收净利拔头筹，国内“狼多肉少”头部企业海外寻订单",
            "features": {
                "keywords": [
                    "药明康德",
                    "营收",
                    "净利",
                    "CXO",
                    "海外订单"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "四大CXO企业2020年成绩单大比拼：药明康德营收净利拔头筹，国内“狼多肉少”头部企业海外寻订单",
            "scores": {
                "News_content": "四大CXO企业2020年成绩单大比拼：药明康德营收净利拔头筹，国内“狼多肉少”头部企业海外寻订单",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业周报：一季报行情开启 建议关注高增长的医药板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "高增长",
                    "医药板块"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药行业周报：一季报行情开启 建议关注高增长的医药板块",
            "scores": {
                "News_content": "医药行业周报：一季报行情开启 建议关注高增长的医药板块",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德（603259.SH）拟认购一专注于医疗健康等领域私募基金份额",
            "features": {
                "keywords": [
                    "药明康德",
                    "认购",
                    "私募基金",
                    "医疗健康"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德（603259.SH）拟认购一专注于医疗健康等领域私募基金份额",
            "scores": {
                "News_content": "药明康德（603259.SH）拟认购一专注于医疗健康等领域私募基金份额",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德现1笔大宗交易 共成交2,203.20万元",
            "features": {
                "keywords": [
                    "药明康德",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "药明康德现1笔大宗交易 共成交2,203.20万元",
            "scores": {
                "News_content": "药明康德现1笔大宗交易 共成交2,203.20万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德今日大宗交易成交15万股，成交价146.88元溢价0.0%",
            "features": {
                "keywords": [
                    "药明康德",
                    "大宗交易",
                    "成交价",
                    "溢价"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "药明康德今日大宗交易成交15万股，成交价146.88元溢价0.0%",
            "scores": {
                "News_content": "药明康德今日大宗交易成交15万股，成交价146.88元溢价0.0%",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "全球CRO市值第一的药明康德交出了好业绩，但估值虚高阴影未散",
            "features": {
                "keywords": [
                    "药明康德",
                    "CRO",
                    "市值",
                    "业绩",
                    "估值虚高"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "全球CRO市值第一的药明康德交出了好业绩，但估值虚高阴影未散",
            "scores": {
                "News_content": "全球CRO市值第一的药明康德交出了好业绩，但估值虚高阴影未散",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德（603259）：新增订单情况良好 长期看好业绩增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "新增订单",
                    "业绩增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德（603259）：新增订单情况良好 长期看好业绩增长",
            "scores": {
                "News_content": "药明康德（603259）：新增订单情况良好 长期看好业绩增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "中航证券 - 药明康德：成长高确定性，长期看好【公司研究】",
            "features": {
                "keywords": [
                    "药明康德",
                    "成长",
                    "高确定性",
                    "长期看好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中航证券 - 药明康德：成长高确定性，长期看好【公司研究】",
            "scores": {
                "News_content": "中航证券 - 药明康德：成长高确定性，长期看好【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "中航证券维持药明康德买入评级，2020年报点评：成长高确定性，长期看好",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "2020年报",
                    "成长",
                    "高确定性"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中航证券维持药明康德买入评级，2020年报点评：成长高确定性，长期看好",
            "scores": {
                "News_content": "中航证券维持药明康德买入评级，2020年报点评：成长高确定性，长期看好",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "光大证券 - 药明康德：2020年业绩符合预期，未来持续强劲增长可期【公司研究】",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020年业绩",
                    "符合预期",
                    "强劲增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "光大证券 - 药明康德：2020年业绩符合预期，未来持续强劲增长可期【公司研究】",
            "scores": {
                "News_content": "光大证券 - 药明康德：2020年业绩符合预期，未来持续强劲增长可期【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]